Evidence map›Paper›PMID 33296788›Full record

Observational studyDiabetes & metabolic syndrome

Predictors of adverse in-hospital outcome and recovery in patients with diabetes mellitus and COVID-19 pneumonia in Iraq.

Hussein Nafakhi, Mohammed Alareedh, Karrar Al-Buthabhak, Foaad Shaghee, Ahmed Nafakhi, Samet Kasim

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 7 pooled it
0.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 7 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Review
  10. Article
  11. Review
  12. TheViruses · 2022
    Article
  13. Review
  14. Management of Glucocorticoid-Induced Hyperglycemia.Diabetes, metabolic syndrome and obesity : targets and therapy · 2022
    Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hussein NafakhiInternal Medicine Department, Medicine College, University of Kufa, Najaf, Iraq. Electronic address: husseinaf.alnaffakh@uokufa.edu.iq.
Mohammed AlareedhInternal Medicine Department, Medicine College, University of Kufa, Najaf, Iraq. Electronic address: mohammed.alareedh@uokufa.edu.iq.
Karrar Al-ButhabhakInternal Medicine Department, Medicine College, University of Kufa, Najaf, Iraq. Electronic address: kararm.zwain@uokufa.edu.iq.
Foaad ShagheeInternal Medicine Department, Jabir Ibn Hayyan Medical University Faculty of Medicine, Kufa, Iraq. Electronic address: f.fertossy@jmu.edu.iq.
Ahmed NafakhiResearch Unit, Najaf Health Bureau, Ministry of Health, Iraq. Electronic address: nafakh06@gmail.com.
Samet KasimInternal Medicine Department, Medicine College, University of Kufa, Najaf, Iraq. Electronic address: samete.almoula@uokufa.edu.iq.
University of Kufa · IQMinistry of Health · IQ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsThere is limited data about the prognosis and impact of COVID-19 pneumonia on patients with diabetes mellitus (DM). We aimed to assess blood indices, ECG markers of sudden death and malignant arrhythmias on admission, and diabetes lowering drugs as possible predictors of adverse in-hospital outcome and COVID-19 pneumonia recovery status.

methodsA retrospective study included patients with newly diagnosed COVID-19 pneumonia from August 20, to October 5, 2020.

resultsA total of 192 patients with COVID-19 pneumonia were included in the present study, of whom 67 patients had DM. Low lymphocytes % [0.4(0.1-0.9), P = .011] and QTc interval prolongation [0.4(0.1-0.8), P = .022] were associated with increased length of ICU stay. On the other hand, metformin use [0.3(0.2-4), P = .032] and DPP-4 inhibitors use [0.3(0.2-3), P = .040] were associated with decreased length of ICU stay. QTc interval prolongation [0.4(0.1-0.9), P = .017] was associated with increased length of hospital stay, while using metformin [0.4(0.2-3), P = .022] was associated with decreased length of hospital stay. Low lymphocytes % [0.5(0.4-1.6), P = .001], insulin use [0.4(0.3-5), P = .003], and old age [0.5(0.1-2.3), P = .025] were associated with extensive lung injury. The risk for in-hospital death was associated with high neutrophil% [1(1-1.4), P = .045], while metformin use was associated with decreased risk for in-hospital death [0.1(0.1-0.6), P = .025]. Insulin use [0.3(0.2-4), P = .013] was associated with partial recovery following acute COVID pneumonia.

conclusionsMetformin and DPP-4 inhibitors use were associated with favorable in-hospital outcomes, while insulin use was associated with extensive lung injury and post-acute COVID-19 pneumonia partial recovery.

Indexed as

AdultAgedCOVID-19COVID-19 Drug TreatmentDiabetes MellitusDipeptidyl-Peptidase IV InhibitorsHospitalizationHumansHypoglycemic AgentsIraqMetforminMiddle AgedPrognosisRecovery of FunctionRetrospective StudiesTreatment OutcomeDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsMetforminCOVID-19Diabetes mellitusOutcomePneumoniaPredictor

Identifiers

PMID33296788
PMCPMC7832757
OpenAlexW3111430313

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.